HIV infection

被引:81
作者
Bekker, Linda-Gail [1 ]
Beyrer, Chris [2 ]
Mgodi, Nyaradzo [3 ]
Lewin, Sharon R. [4 ,5 ,6 ,7 ]
Delany-Moretlwe, Sinead [8 ]
Taiwo, Babafemi [9 ]
Masters, Mary Clare [9 ]
Lazarus, Jeffrey V. [10 ,11 ]
机构
[1] Univ Cape Town, Desmond Tutu HIV Ctr, RSA, Cape Town, South Africa
[2] Duke Univ, Duke Global Hlth Inst, Durham, NC USA
[3] Univ Zimbabwe, Clin Trials Res Ctr, Harare, Zimbabwe
[4] Univ Melbourne, Dept Infect Dis, Peter Doherty Inst Infect & Immun, Melbourne, Vic, Australia
[5] Royal Melbourne Hosp, Victorian Infect Dis Serv, Peter Doherty Inst Infect & Immun, Melbourne, Vic, Australia
[6] Alfred Hosp, Dept Infect Dis, Melbourne, Vic, Australia
[7] Monash Univ, Melbourne, Vic, Australia
[8] Univ Witwatersrand, Wits RHI, Johannesburg, South Africa
[9] Northwestern Univ, Div Infect Dis, Chicago, IL USA
[10] CUNY, Grad Sch Publ Hlth & Hlth Policy, New York, NY USA
[11] Univ Barcelona, Hosp Clin, Barcelona Inst Global Hlth ISGlobal, Barcelona, Spain
基金
澳大利亚国家健康与医学研究理事会; 英国医学研究理事会;
关键词
HUMAN-IMMUNODEFICIENCY-VIRUS; CD4(+) T-CELLS; ACTIVE ANTIRETROVIRAL THERAPY; DAPIVIRINE VAGINAL RING; MIDDLE-INCOME COUNTRIES; PREEXPOSURE PROPHYLAXIS; MALE CIRCUMCISION; NEUTRALIZING ANTIBODIES; IATROGENIC TRANSMISSION; REVERSE-TRANSCRIPTASE;
D O I
10.1038/s41572-023-00452-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The AIDS epidemic has been a global public health issue for more than 40 years and has resulted in similar to 40 million deaths. AIDS is caused by the retrovirus, HIV-1, which is transmitted via body fluids and secretions. After infection, the virus invades host cells by attaching to CD4 receptors and thereafter one of two major chemokine coreceptors, CCR5 or CXCR4, destroying the host cell, most often a T lymphocyte, as it replicates. If unchecked this can lead to an immune-deficient state and demise over a period of similar to 2-10 years. The discovery and global roll-out of rapid diagnostics and effective antiretroviral therapy led to a large reduction in mortality and morbidity and to an expanding group of individuals requiring lifelong viral suppressive therapy. Viral suppression eliminates sexual transmission of the virus and greatly improves health outcomes. HIV infection, although still stigmatized, is now a chronic and manageable condition. Ultimate epidemic control will require prevention and treatment to be made available, affordable and accessible for all. Furthermore, the focus should be heavily oriented towards long-term well-being, care for multimorbidity and good quality of life. Intense research efforts continue for therapeutic and/or preventive vaccines, novel immunotherapies and a cure. In HIV infection, the virus invades and destroys the immune system of the host. This Primer by Bekker and colleagues summarizes the epidemiology, mechanisms, diagnosis and treatment of HIV infection, and discusses patient quality of life and open research questions for this condition.
引用
收藏
页数:21
相关论文
共 280 条
[61]   High GUD Incidence in the Early 20th Century Created a Particularly Permissive Time Window for the Origin and Initial Spread of Epidemic HIV Strains [J].
de Sousa, Joao Dinis ;
Mueller, Viktor ;
Lemey, Philippe ;
Vandamme, Anne-Mieke .
PLOS ONE, 2010, 5 (03)
[62]   Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021 [J].
Deeks, Steven G. ;
Archin, Nancie ;
Cannon, Paula ;
Collins, Simon ;
Jones, R. Brad ;
de Jong, Marein A. W. P. ;
Lambotte, Olivier ;
Lamplough, Rosanne ;
Ndung'u, Thumbi ;
Sugarman, Jeremy ;
Tiemessen, Caroline T. ;
Vandekerckhove, Linos ;
Lewin, Sharon R. .
NATURE MEDICINE, 2021, 27 (12) :2085-2098
[63]   HIV infection [J].
Deeks, Steven G. ;
Overbaugh, Julie ;
Phillips, Andrew ;
Buchbinder, Susan .
NATURE REVIEWS DISEASE PRIMERS, 2015, 1
[64]   HIV Infection, Inflammation, Immunosenescence, and Aging [J].
Deeks, Steven G. .
ANNUAL REVIEW OF MEDICINE, VOL 62, 2011, 2011, 62 :141-155
[65]   What determines health-related quality of life among people living with HIV: An updated review of the literature [J].
Degroote S. ;
Vogelaers D. ;
Vandijck D.M. .
Archives of Public Health, 72 (1)
[66]  
DeJesus E, 2018, AIDS RES HUM RETROV, V34, P337, DOI [10.1089/aid.2017.0203, 10.1089/AID.2017.0203]
[67]   Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial [J].
Delany-Moretlwe, Sinead ;
Hughes, James P. ;
Bock, Peter ;
Ouma, Samuel Gurrion ;
Hunidzarira, Portia ;
Kalonji, Dishiki ;
Kayange, Noel ;
Makhema, Joseph ;
Mandima, Patricia ;
Mathew, Carrie ;
Spooner, Elizabeth ;
Mpendo, Juliet ;
Mukwekwerere, Pamela ;
Mgodi, Nyaradzo ;
Ntege, Patricia Nahirya ;
Nair, Gonasagrie ;
Nakabiito, Clemensia ;
Nuwagaba-Biribonwoha, Harriet ;
Panchia, Ravindre ;
Singh, Nishanta ;
Siziba, Bekezela ;
Farrior, Jennifer ;
Rose, Scott ;
Anderson, Peter L. ;
Eshleman, Susan H. ;
Marzinke, Mark A. ;
Hendrix, Craig W. ;
Beigel-Orme, Stephanie ;
Hosek, Sybil ;
Tolley, Elizabeth ;
Sista, Nirupama ;
Adeyeye, Adeola ;
Rooney, James F. ;
Rinehart, Alex ;
Spreen, William R. ;
Smith, Kimberly ;
Hanscom, Brett ;
Cohen, Myron S. ;
Hosseinipour, Mina C. .
LANCET, 2022, 399 (10337) :1779-1789
[68]   HIV infection among persons who inject drugs: ending old epidemics and addressing new outbreaks [J].
Des Jarlais, Don C. ;
Kerr, Thomas ;
Carrieri, Patrizia ;
Feelemyer, Jonathan ;
Arasteh, Kamyar .
AIDS, 2016, 30 (06) :815-825
[69]  
Devereux HL, 1999, AIDS, V13, pF123, DOI 10.1097/00002030-199912240-00001
[70]  
DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents, 2022, GUIDELINES USE ANTIR